First and foremost, I would like to express my deepest condolences and sympathies to those who have been affected and facing challenges by the 2024 Noto Peninsula Earthquake and the tragic plane crash at Haneda Airport. We pray for the swift recovery of the affected region.

The pharmaceutical business and industry environment surrounding us continue to undergo rapid changes, and we are being challenged to adapt quickly and effectively to sustain growth by identifying their strengths and weaknesses. As we reflect on the year 2023, I think we achieved our year plan, such as the expansion of our products and the execution of our business plan, through the diligent efforts of all regions and functions to achieve their targets. The discontinuation of several development projects were difficult decisions, and we reaffirmed the need to clearly indicate life-changing values to advance creating new medicines of the future. We have seriously considered what is necessary for greater long-term potential for patients and the business.

One such action was the acquisition of Orchard Therapeutics, which we announced in October 2023. We believe that its platform technology, hematopoietic stem cell (HSC) gene therapy, has the potential to treat diseases fundamentally for which there has been no effective treatment, which aligns with our Vision of life-changing value and is expected to be realized by society. We explore more opportunities to enrich our pipelines and with the modalities that are necessary for growth and continue to strategic investment. Additionally, in Japan we reorganized the Research and Development functions, which we announced in December 2023. By reorganizing Research and Development into solid global organizational frameworks, we aim to create an environment necessary for generating innovations in Research and provide Development units with systems aligned with the potential of their products, enabling us to prioritize value maximization and accelerate the delivery of solutions to as many patients in need as possible.

Masashi Miyamoto, Ph.D.
Representative Director, President and
Chief Executive Officer

To bridge these actions and the realization of our Vision, each and every one of us must possess a strong determination to “create medicines with life-changing value and make people smile” and to challenge ourselves without being satisfied with the status quo, and to continue to learn and grow beyond our past successes. I am convinced that we can make even more people smile by executing all our actions not just additions but multiplications of each other's strengths.

Kyowa Kirin has paved the way for growth by researching, developing, and delivering drugs that address unmet medical needs. Behind this success lies a history of undertaking daring challenges, including various failures, re-starting from those failures, adapting to changes in the business environment, and restructuring strategies. I begin the new year with a strong belief that we will cultivate drug discovery capabilities that will enable the continuous creation of life-changing value in the future. We aim to achieve a strong growth as a Japan-based Global Specialty Pharmaceutical company. I look forward to your continued support and cooperation throughout this year!

Masashi Miyamoto, Ph.D.
Representative Director, President and Chief Executive Officer

DownloadPDF file

More Kyowa Kirin "Growth" Stories

Kyowa Kirin launches the CTCL Global Care Collaborative’s Time to Act global consensus statement

Patients | May 13, 2024

Kyowa Kirin Global Corporate Planning Head Shoko Itagaki’s Message for International Women's Day

People & Culture | March 8, 2024

Kyowa Kirin celebrates Rare Disease Day 2024 across the world

Patients | February 9, 2024

Kyowa Kirin CEO Miyamoto’s New Year Message

Growth | January 9, 2024

Kyowa Kirin Chief International Business Officer Abdul Mullick’s Message on UN’s International Day of Persons with Disabilities

Sustainability | December 1, 2023

Kyowa Kirin hosted a booth for the first time at the Tokyo Rainbow Pride 2023 [Our Diversity, Equity & Inclusion]

People & Culture | November 9, 2023

Our Stable Supply of High-quality Pharmaceuticals

Sustainability | September 20, 2023

Provide pharmaceuticals for unmet medical needs - A Conversation with Kyowa Kirin’s R&D Executives

Innovation | August 22, 2023PDF file

Ensure a Thriving Global Environment for Future Generations

Sustainability | July 28, 2023

“Menstruation” and “fertility treatment” felt like taboo subjects in the workplace - Why be open about issues unique to women? PartⅡ

People & Culture | June 9, 2023

How Kyowa Kirin Celebrated Rare Disease Day 2023 around The World

Patients | May 18, 2023

“Menstruation” and “fertility treatment” felt like taboo subjects in the workplace - Why be open about issues unique to women? PartⅠ

People & Culture | April 25, 2023

Kyowa Kirin CEO Miyamoto’s Message on Rare Disease Day

Patients | February 28, 2023

Promoting patient advocacy and nurturing patient-centric care: Interview with Kyowa Kirin North America

Patients | February 14, 2023

Celebrating another year of diverse initiatives around the world: RDD 2022 in EMEA

Patients | January 24, 2023

Celebrating another year of diverse initiatives around the world: RDD 2022 in North America

Patients | December 15, 2022

Celebrating another year of diverse initiatives around the world: RDD 2022 in Asia Pacific

Patients | November 21, 2022

Celebrating another year of diverse initiatives around the world: RDD 2022 in Japan

Patients | October 20, 2022

Providing high-quality pharmaceuticals to patients around the world

Sustainability | September 22, 2022

Striving to create life-changing “Only-one value” that brings smiles to patients

Innovation | July 25, 2022

Kyowa Kirin International: It's Time to Shine A Light on XLH

Patients | June 27, 2022

Kyowa Kirin CEO Miyamoto’s Message on Pride Month

People & Culture | June 9, 2022

Kyowa Kirin International Celebrates the UN’s International Day of Persons with Disabilities in EMEA

People & Culture | January 20, 2022

Kyowa Kirin International: Around the world challenge

People & Culture | December 17, 2021Open in new window

Kyowa Kirin North America: Honoring The Caregiver, Everyday Heroes, During National Family Caregivers Month

Patients | November 19, 2021

Kyowa Kirin's Effort to Realize a Sustainable Society

Sustainability | October 11, 2021

Our Financial Strategy for Creating Life-changing Value

Growth | September 9, 2021

Changes in society caused by COVID-19 and the impact on Kyowa Kirin

Growth | August 19, 2021

Bio Adventure Hands-On Experience Sessions: Become a drug discovery researcher During Your Summer Break

Sustainability | July 27, 2021

AMGEN AND KYOWA KIRIN TO JOINTLY DEVELOP AND COMMERCIALIZE KHK4083, A PHASE 3-READY, POTENTIAL FIRST-IN-CLASS TREATMENT FOR ATOPIC DERMATITIS

News Release | June 1, 2021

MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting

News Release | May 20, 2021

White Paper on the unrecognized burden of XLH in adults in Europe

Patients | July 13, 2020

Empowering Children to Ask "Why?": Tohoku University Science Campus Hands-On Science Lessons (First Half)

People & Culture | March 5, 2020

Empowering Children to Ask "Why?": Tohoku University Science Campus Hands-On Science Lessons (Second Half)

People & Culture | March 5, 2020

“Delivering smiles with sports” Creating an inclusive society through table tennis

Sustainability | January 14, 2020

Bio Adventure*: Kyowa Kirin Invites Children to a Science Adventure

People & Culture | July 3, 2019

Return to Stories